Anja Bastian, Jessica E. Thorpe, Bryan C. Disc, Lora C. Bailey-Down, Aleem Gangjee, Ravi K. Devambatla, Jim Henthorn, Kenneth M. Humphries, Shraddha S. Vadvalkar, Michael A. Ihnat

The Journal of Pharmacology and Experimental Therapeutics




Figure S1. AG311 shows a steep dose response curve.

MDA-MB-435 cells were treated with multiple doses of AG311, pemetrexed (Pem), or doxorubicin (Dox) to establish a dose response. Viability was assessed after 48 hours with PrestoBlue.

Anja Bastian, Jessica E. Thorpe, Bryan C. Disc, Lora C. Bailey-Down, Aleem Gangjee, Ravi K. Devambatla, Jim Henthorn, Kenneth M. Humphries, Shraddha S. Vadvalkar, Michael A. Ihnat

The Journal of Pharmacology and Experimental Therapeutics




Figure S2. AG311 induced membrane permeability in MDA-MB-435 spheroids.

MDA-MB-435 spheroids were cultured for 12 days and treated with AG311 (25  $\mu$ M) in the presence of SYTOX Green. Images were acquired every 5 minutes.

Anja Bastian, Jessica E. Thorpe, Bryan C. Disc, Lora C. Bailey-Down, Aleem Gangjee, Ravi K. Devambatla, Jim Henthorn, Kenneth M. Humphries, Shraddha S. Vadvalkar, Michael A. Ihnat

The Journal of Pharmacology and Experimental Therapeutics




Figure S3. AG311 does not induce apoptosis.

**A)** Whole cell lysates were collected from AG311 (20  $\mu$ M) or staurosporine (STS, 1  $\mu$ M) treated MDA-MB-435 cells and western blot analysis performed for the presence of cleaved PARP. **B)** Cells were treated with AG311 (25  $\mu$ M) in 15-minute intervals or doxorubicin (dox) (1 $\mu$ M, 12 hours), followed by measuring caspase 3 and 7 activity.

Anja Bastian, Jessica E. Thorpe, Bryan C. Disc, Lora C. Bailey-Down, Aleem Gangjee, Ravi K. Devambatla, Jim Henthorn, Kenneth M. Humphries, Shraddha S. Vadvalkar, Michael A. Ihnat

The Journal of Pharmacology and Experimental Therapeutics




Figure S4. AG311-induced cell death is not inhibited by cyclosporine A

MDA-MB-435 cells were treated with AG311 or cyclosporine A (CsA), or cotreated with both agents. Viability was assessed with PrestoBlue 24 hours after treatment.

Anja Bastian, Jessica E. Thorpe, Bryan C. Disc, Lora C. Bailey-Down, Aleem Gangjee, Ravi K. Devambatla, Jim Henthorn, Kenneth M. Humphries, Shraddha S. Vadvalkar, Michael A. Ihnat

The Journal of Pharmacology and Experimental Therapeutics




Figure S5. IC<sub>50</sub> values of AG311 on different cell densities

Cells (4T1-luc2-GFP) were plated at different densities and treated with AG311 for 30 hours. Viability was assessed with PrestoBlue 30 hours after treatment. IC<sub>50</sub> are shown in parentheses.